Which medications in the drug class Potassium Channel Blockers are used in the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)?

Updated: May 23, 2019
  • Author: David E Stickler, MD; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
  • Print

Potassium Channel Blockers

Blocking voltage-dependent potassium channels prolongs presynaptic cell membrane depolarization, which enhances calcium transport into nerve endings.

Amifampridine (Firdapse, Ruzurgi)

Increases intracellular calcium concentrations in nerve endings by blocking voltage-dependent potassium channels. The increased calcium facilitates exocytosis of acetylcholine-containing vesicles, which, in turn, enhances neuromuscular transmission. It is indicated for LEMS in adults and children as young as 6 years old.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!